Rationale and design of the "Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled" trial (TOCIBRAS).
Farias DLC, Prats J, Cavalcanti AB, Rosa RG, Machado FR, Berwanger O, Azevedo LCP, Lopes RD, Avezum Á, Kawano-Dourado L, Damiani LP, Rojas SSO, Oliveira CZ, Andrade LEC, Sandes AF, Pintão MC, Castro Júnior CG, Scheinberg P, Veiga VC.
Farias DLC, et al.
Rev Bras Ter Intensiva. 2020 Jul-Sep;32(3):337-347. doi: 10.5935/0103-507X.20200060.
Rev Bras Ter Intensiva. 2020.
PMID: 32965395
Free PMC article.